Joint involvement in chronic inflammatory bowel disease - Current diagnostics and treatment options;Gelenkbeteiligung bei chronisch entzündlichen darmerkrankungen - Aktuelle diagnostik und therapiemöglichkeiten

Zeitschrift fur Gastroenterologie

Volumn 44, Issue 6, 2006, Pages 497-502

  Becker, Heidemarie ^a   Gaubitz, M ^a   Domschke, W ^a   Kucharzik, T ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Colitis ulcerosa; Crohn's disease; Extraintestinal manifestation; Inflammatory bowel disease

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; HLA B27 ANTIGEN; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; CLINICAL ASSESSMENT; DIAGNOSTIC PROCEDURE; ENTERITIS; ENTHESITIS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; REVIEW; SACROILIITIS; SPONDYLOARTHROPATHY; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ARTHRALGIA; ARTHRITIS; CHRONIC DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; PHYSICAL THERAPY MODALITIES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33745750525     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926586     Document Type: Review

References (76)

1. Adler G, Reinshagen M. (Leitlinie der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten: Diagnostik und Therapie des M. Crohn). Extraintestinale Manifestationen. Z Gastroenterol 2003; 41: 54-61
2. Reinshagen M, Fölsch UR. (Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten). Extraintestinale Manifestationen bei Colitis ulcerosa. Z Gastroenterol 2004; 42: 1024-1028
3. Hoffmann JC, Zeitz M. S3-Leitlinie der Deutschen Gesellschaft für Verdauungs-und Stoffwechselerkrankungen und des Kompetenznetzes chronisch entzündliche Darmerkrankungen zur Diagnostik und Therapie der Colitis ulcerosa. Ein Update. Med Klinik 2005; 100, 1: 43-50
4. De Vlam K, Mielants H, Cuvelier C et al. Spondylarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27 (12): 2860-2865
5. Salvarani C, Vlachonikolis IG, van der Heijde CM et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001; 36 (12): 1307-1313
6. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-391
7. Palm O, Moum B, Jahnsen J et al. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001; 40: 1256-1261
8. Palm O, Moum B, Ongre A et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002; 29: 511-515
9. Healy PJ, Helliwell PS. Classification of the spondylarthropathies. Curr Opin Rheumatol 2005; 17: 395-399
10. Holden W, Orchard T, Wordsworth P. Enteropathic arthritis. Rheum Dis Clin North Am 2003; 29: 513-530
11. Schorr-Lesnick B, Brandt LJ. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83: 216-223
12. Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-1227
13. Wollheim FA. Enteropathic arthritis: how do the joints talk with the gut? Curr Opin Rheumatol 2001; 13: 305-309
14. Orchard TR, Thiyagaraja S, Welsh KI et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274-278
15. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67
16. Calin A, Porta J, Fries JF et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977; 237: 2613-2614
17. Rudwaleit M, Sieper J. Diagnose und Frühdiagnose der ankylosierenden Spondylitis (Morbus Bechterew). Z Rheumatol 2004; 63: 193-202
18. De Vos M. Joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl 4): 36-42
19. Baeten D, de Keyset H, Veys EM. Ankylosing spondylitis and bowel disease. Best Practice & Research Clin Rheumatol 2002; 16 (4): 537-549
20. Laukens D, Peeters H, Marichal D et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 2005; 64 (6): 930-935
21. Lambert R, Dhillon S, Jhangri G et al. High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: Deltoid origin involvement constitutes a hallmark of disease. Arthritis Rheum 2004; 51: 681-690
22. Olivieri I, Barozzi L, Padula A. Enthesiopathy: clinical manifestations, imaging and treatment. Baillieres Clin Rheumatol 1998; 12 (4): 665-681
23. Klingenstein G, Levy RN, Kornbluth A et al. Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther 2005; 21: 243-249
24. Ogihara M, Masaki T, Watanabe T et al. Psoas abscess complicating Crohn's disease: report of a case. Surg Today 2000; 30: 759-763
25. Klaus J, Armbrecht G, Steinkamp M et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51: 654-658
26. Buskila D, Odes LR, Neumann L et al. Fibromyalgia in inflammatory bowel disease. J Rheumatol 1999; 26: 1167-1171
27. Palm O, Mourn B, Jahnsen J et al. Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. J Rheumatol 2001; 28: 590-594
28. Toussirot E, Wendling D. Crohn's disease associated with seropositive rheumatoid arthritis. Clin Exp Rheumatol 1997; 15: 307-311
29. Majka D, Holers V. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arthritis Rheum 2003; 48: 2701-2705
30. Sauerland U, Becker H, Seidel M et al. Clinical utility of the anti-CCP assay: Experiences with 700 patients. Ann NY Acad Sci 2005; 1050: 314-318
31. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-715
32. Gunnarsson I, Kanerud L, Pettersson E et al. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997; 36: 1089-1094
33. Kirkpatrick AW, Bookman AA, Habal F. Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. Can J Gastroenterol 1999; 13: 159-162
34. Deutsche Gesellschaft für Rheumatologie. Qualitätssicherung in der Rheumatologie. Fassung vom 25.9.2003; 5.3.13; www.rheumanet.org
35. Backhaus M, Burmester GR, Gerber T et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60: 641-649
36. Lehtinen A, Taavitsainen M, Leirisalo-Repo M. Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. Clin Exp Rheumatol 1994; 12: 143-148
37. Schmidt WA, Hauer R-W, Banzer D et al. Technik und Stellenwert der Arthrosonographie in der rheumatologischen Diagnostik. Z Rheumatol 2002; 61: 279-290
38. Van der Heijde D, Ladewé R. Imaging in spondylitis. Curr Opin Rheumatol 2005; 17: 413-417
39. Braun J, Bollow M, Eggens U et al. Use of dynamic magnetic resonance tomography in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37: 1039-1045
40. Bollow M, Braun J, Hamm B et al. Early sacroiliitis in patients with spondylarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. Radiology 1995; 194: 529-536
41. Muche B, Bollow M, Francois RJ et al. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003; 48: 1374-1384
42. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513-516
43. Evans JMM, McMahon AD, Murray FE et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997; 40: 619-622
44. Felder JB, Korelitz BI, Rajapakse R et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000; 95: 1949-1954
45. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 751-757
46. Mahadevan U, Loftus Jr EV, Tremaine WJ et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 910-914
47. Matuk R, Crawford J, Abreu MT et al. The spectrum of gastrointestinal toxicity and effects on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 352-356
48. Hatz H. Intraartikuläre und periartikuläre Therapie. In: Hatz H (Hrsg). Lokale intraartikuläre Diagnostik und Therapie. Bremen: UNI-MED, 2005: 2. Auflage: 34-80
49. Ballow M, Braun J, Taupitz M et al. Intraarticular corticosteroid injection into the sacroiliac joints using CT guidance in patients with spondylarthropathy: Indication and follow-up with contrast-enhanced MRI. J Comp Assist Tomo 1996; 20: 512-521
50. Hanly JG, Mitchell M, MacMillan L et al. Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondylarthropathy: Results of a six month study. Arthritis Rheum 1998; 41 (Suppl S111): 20
51. Mease PJ. Psoriatic arthritis therapy advances. Curr Opin Rheumatol 2005; 17: 426-432
52. Zochling J, Braun J. Management and treatment of ankylosing spondylitis. Curr Opin Rheumatol 2005; 17: 418-425
53. Braun J, Alten R, Burmester G et al. A placebo-controlled multicenter study of the efficacy and tolerance of sulfasalazine in early undifferentiated spondylarthropathy. Ann Rheum Dis 2004; 63, Suppl 1: 413
54. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M et al. Efficacy of methotrexate in ankylosing spondylitis: A randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31: 1568-1574
55. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2003; 1: CD003459
56. Van Denderen JC, van der Horst-Bruinsma I, Bezemer PD et al. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol 2003; 30: 1558-1560
57. Ammer K. Physiotherapy in seronegative spondylarthropathies - a systematic review. Eur J Phys Med Rehabil 1997; 7: 114-119
58. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2004; 4: CD002822
59. Schmidt KL. Rheumatische Erkrankungen. In: Schmidt KL, Drexel H, Jochheim KA (Hrsg). Lehrbuch der physikalischen Medizin und Rehabilitation. Stuttgart: Gustav Fischer, 1995: 329-345
60. Braun J, Pham T, Sieper J et al. International ASAS consensus Statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-824
61. Manger B. Überarbeitete Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich rheumatischen Erkrankungen. Z Rheumatol 2002; 61: 694-697
62. Anandarajah A, Ritchlin CT. Treatment update on spondylarthropathy. Curr Opin Rheumatol 2005; 17: 247-256
63. Rudwaleit M, Listing J, Brandt J et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-670
64. Van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-591
65. Generini S, Giacomelli R, Fedi R et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63: 1664-1669
66. Kaufman I, Caspi D, Yeshurun D et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol International 2005; 25: 406-410
67. Van den Bosch F, Kruithof E, De Vos M et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356:1821-1822
68. Marzo-Ortega H, McGonagle D, O'Connor P et al. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74-76
69. Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46: 766-773
70. Kommission Pharmakotherapie. Stellungnahme der Deutschen Gesellschaft für Rheumatologie zur Therapie der ankylosierenden Spondylitis (AS) mit Radiumchlorid (224SpondylAT). Z Rheumatol 2001; 60: 84-87
71. Monsen U, Sorstad J, Hellers G et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990; 85: 711-716
72. Thomas PD, Keat AC, Forbes A et al. Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy. Eur J Gastroenterol Hepatol 1999; 11: 1001-1005
73. Andreyev HJN, Kamm MA, Forbes A et al. Joint symptoms after restorative proctocolectomy in ulcerative colitis and familial polyposis coli. J Clin Gastroenterol 1996; 23: 35-39
74. Ter Borg EJ, Nadorp JH, Elbers JR. Ileal pouch arthritis: a case report. Eur J Gastroenterol Hepatol 1996; 8: 957-959
75. Isdale A, Wright V. Seronegative arthritis and the bowel: the gut and rheumatic diseases. Baillière's Clin Rheumatol 1989; 3: 285-301
76. Orchard TR, Jewell DP. The importance of ileocaecal integrity in the arthritic complications of Crohn's disease. Inflamm Bowel Dis 1999; 5: 92-97